Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma

Journal of Bone and Mineral Research

Volumn 20, Issue 3, 2005, Pages 480-486

  Mazziotti, Gherardo ^a   Sorvillo, Francesca ^a   Piscopo, Marco ^a   Cioffi, Michele ^a   Pilla, Paola ^a   Biondi, Bernadette ^b   Iorio, Sergio ^a   Giustina, Andrea ^c   Amato, Giovanni ^a   Carella, Carlo ^a,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d University of Brescia ^*  (Italy)

Author keywords

Bone metabolism; Osteoprotegerin; Subclinical thyrotoxicosis; Thyroid hormone; Thyrotropin

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; LEVOTHYROXINE; OSTEOPROTEGERIN; RECOMBINANT THYROTROPIN; THYROTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MONITORING; POSTMENOPAUSE; THYROID CARCINOMA; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY; THYROTOXICOSIS;

ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; BONE RESORPTION; CARCINOMA; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 20044380721     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.041126     Document Type: Article

References (36)

1. Oikawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, Ogihara H, Ishigaki J, Inoue T 1999 Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol 50:171-176.
2. Isaia GC, Roggia C, Gola D, Stefano MD, Gallone G, Aimo G, Ardissone P, Mussetta M 2000 Bone turnover in hyperthyroidism before and after thyrostatic management. J Endocrinol Invest 23:727-731.
3. Pantazi H, Papapetrou PD 2000 Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099-1106.
4. Akalin A, Colak O, Alatas O, Efe B 2002 Bone remodeling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 57:125-129.
5. Vestergaard P, Mosekilde L 2003 Hyperthyroidism, bone mineral, and fracture risk-A meta-analysis. Thyroid 13:585-593.
6. Greenspan SL, Greenspan FS 1999 The effect of thyroid hormone on skeletal integrity. Ann Intern Med 130:750-758.
7. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM 1999 Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 84:435-439.
8. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C 2004 High serum osteoprotegerin levels in patients with hyperthyroidism: Effect of medical treatment. Bone 35:785-791.
9. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, AMGEN EST Program, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
11. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
12. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M 2003 TSH is a negative regulator of skeletal remodeling. Cell 115:129-130.
13. Tsai JA, Janson A, Bucht E, Kindmark H, Marcus C, Stark A, Zemack HR, Torring O 2004 Weak evidence of thyrotropin receptors in primary cultures of human osteoblast-like cells. Calcif Tissue Int 74:486-491.
14. Vestergaard P, Mosekilde L 2002 Fractures in patients with hyperthyroidism and hypothyroidism: A nationwide follow-up study in 16,249 patients. Thyroid 12:411-419.
15. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y 2000 Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157-4161.
16. Bauer DC, Nevitt MC, Ettinger B, Stone K 1997 Low thyrotropin levels are not associated with bone loss in older women: A prospective study. J Clin Endocrinol Metab 82:2931-2936.
17. Guo CY, Weetman AP, Eastell R 1997 Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 46:301-307.
18. Toivonen J, Tahtela R, Laitinen K, Risteli J, Valimaki MJ 1998 Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138:667-673.
19. Meier C, Beat M, Guglielmetti M, Christ-Grain M, Staub JJ, Kraenzlin M 2004 Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: A randomized controlled trial. Osteoporos Int 15:209-216.
20. Ladenson PW 1999 Recombinant human thyrotropin symposium. Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid 9:429-433.
21. Robbins R, Tuttle R, Sharaf R, Larson S, Robbins H, Ghossein R, Smith A, Drucher W 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625.
22. Ringel MD, Ladenson PW 2004 Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 11:97-116.
23. Reginster JY, Dethor M, Pirenne H, Dewe W, Albert A 1998 Reproducibility and diagnostic sensitivity of ultrasonometry of the phalanges to assess osteoporosis. Int J Gynaecol Obstet 63:21-28.
24. Wuster C, Albanese C, De Aloysio D, Duboeuf F, Gambacciani M, Gonnelli S, Gluer CC, Hans D, Joly J, Reginster JY, De Terlizzi F, Cadossi R 2000 Phalangeal osteosonogrammetry study: Age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. J Bone Miner Res 15:1603-1614.
25. Novack DV 2003 TSH, the bone suppressing hormone. Cell 115:129-130.
26. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA 291:228-238.
27. Schneider R, Reiners C 2003 The effect of levothyroxine therapy on bone mineral density: A systematic review of the literature. Exp Clin Endocrinol Diabetes 111:455-470.
28. Sorvillo F, Mazziotti G, Carbone A, Piscopo M, Rotondi M, Cioffi M, Musto P, Biondi B, Iorio S, Amato G, Carella C 2003 Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 88:4818-4822.
29. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H 1998 Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615.
30. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527.
31. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360.
32. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P 2001 Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145:685-690.
33. Misra M, Soyka LA, Miller KK, Herzog DB, Grinspoon S, De Chen D, Neubauer G, Klibanski A 2003 Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88:3816-3822.
34. Canalis E 2003 Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15:454-457.
35. Varga F, Spitzer S, Klaushofer K 2004 Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1, 25D(3)) inversely regulate OPG gene expression in dependence of osteoblastic phenotype. Calcif Tissue Int 74:382-387.
36. Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE 2002 Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86:642-650.